India's Piramal Adds Four Pfizer Consumer Brands Pursuing Market Lead
This article was originally published in The Tan Sheet
Executive Summary
The consumer goods arm of Piramal Enterprises makes its third acquisition in six months, keeping up a hectic deal-making pace in its quest to be one of India’s leading OTC players.
You may also be interested in...
Piramal Boosts N American Capacity With Ash Stevens Deal
Cash-flush Piramal Enterprises is ramping up its North American drug manufacturing operations through the purchase of Ash Stevens, a US company making high-potency active pharmaceutical ingredients, in the latest in a string of deals for the unconventional Indian group.
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.